Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06424379
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-16
Brief Title:
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Study of Clinical Histological Immunohistochemical and Molecular Impact of BCL6 Gene Rearrangement in Most Prevalent Non-Hodgkin Lymphomas
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BCL6-RINHL
Brief Summary:
Non-Hodgkin lymphomas NHLs constitute a heterogeneous group of malignant neoplasms with diverse clinical behaviors and distinct pathologic and molecular characteristics Among these lymphomas follicular lymphomas FLs marginal zone lymphomas MZLs and diffuse large B-cell lymphomas DLBCLs emerge as the most prevalent entities While FL and MZL are representative of indolent B-cell lymphomas characterized by a slow progression of the disease and favorable clinical outcomes DLBCL stands out as an aggressive lymphoma often occuring from the transformation of a pre-existing indolent lymphoma
Chromosome translocations are a hallmark of some NHL subtypes offering insights into their molecular pathogenesis For instance the conventional FL is genetically characterized by the t1418 chromosomal translocation found in 85-90 of cases resulting in sustained elevation of the antiapoptotic protein B-cell lymphoma 2 BCL2 However certain FL cases lack BCL2 translocations and exhibit distinct clinical morphological and phenotypical features with genetic heterogeneity
A subset of BCL2-negative FLs displays rearrangements within chromosomal region 3q27 inducing abnormal modulation of B-cell lymphoma 6 BCL6 expression The BCL6 gene plays a critical role in germinal center development and B-cell differentiation Previous investigations indicate that BCL6 rearrangements BCL6-R manifest distinct pathological and genetic features diverging from classical FL presentations
FLs carrying BCL6-R commonly share a specific CD10- Bcl-2- Bcl-6 phenotype often accompanied by a monocytoid component and increased frequency of diffuse architectural patterns Patients with BCL6-R tend to exhibit advanced clinical stages and complex genetic profiles
MZLs present differential diagnostic challenges due to shared monocytoid components phenotypes traits and common genetic features The similarities observed between BCL6-R FL and MZL suggest a convergence in both morphological and genetic aspects leading to intricate differentiation Traditionally these indolent NHLs with BCL6-R were categorized as FL and incorporated into the FL category in the WHO classification However few studies highlight the occurrence of BCL6-R in MZLs This observation gives rise to the hypothesis that indolent NHLs exhibiting BCL6-R might correspond to a continuum comprising both FL and MZL
Additionally BCL6-R has been frequently documented in DLBCL cases with residual MZL component These DLBCL cases might display a mutational profile reminiscent of MZL This suggests a plausible origin of BCL6-R DLBCL from indolent BCL6-R MZLs or BCL6-R FLs cases
Chromosome translocations are a hallmark of some NHL subtypes offering insights into their molecular pathogenesis For instance the conventional FL is genetically characterized by the t1418 chromosomal translocation found in 85-90 of cases resulting in sustained elevation of the antiapoptotic protein B-cell lymphoma 2 BCL2 However certain FL cases lack BCL2 translocations and exhibit distinct clinical morphological and phenotypical features with genetic heterogeneity
A subset of BCL2-negative FLs displays rearrangements within chromosomal region 3q27 inducing abnormal modulation of B-cell lymphoma 6 BCL6 expression The BCL6 gene plays a critical role in germinal center development and B-cell differentiation Previous investigations indicate that BCL6 rearrangements BCL6-R manifest distinct pathological and genetic features diverging from classical FL presentations
FLs carrying BCL6-R commonly share a specific CD10- Bcl-2- Bcl-6 phenotype often accompanied by a monocytoid component and increased frequency of diffuse architectural patterns Patients with BCL6-R tend to exhibit advanced clinical stages and complex genetic profiles
MZLs present differential diagnostic challenges due to shared monocytoid components phenotypes traits and common genetic features The similarities observed between BCL6-R FL and MZL suggest a convergence in both morphological and genetic aspects leading to intricate differentiation Traditionally these indolent NHLs with BCL6-R were categorized as FL and incorporated into the FL category in the WHO classification However few studies highlight the occurrence of BCL6-R in MZLs This observation gives rise to the hypothesis that indolent NHLs exhibiting BCL6-R might correspond to a continuum comprising both FL and MZL
Additionally BCL6-R has been frequently documented in DLBCL cases with residual MZL component These DLBCL cases might display a mutational profile reminiscent of MZL This suggests a plausible origin of BCL6-R DLBCL from indolent BCL6-R MZLs or BCL6-R FLs cases
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None